Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Daily short sale tracking: Ambev SA's short volume increased by 4 million, with a short sale ratio of 10%
J&J Releases Encouraging Data on Talvey Combination Therapies
Bristol-Myers Squibb Options Spot-On: On September 27th, 99,897 Contracts Were Traded, With 833.89K Open Interest
Unusual Options Activity: UGI, TSLA and Others Attract Market Bets, UGI V/OI Ratio Reaches 197.4
Sector Update: Health Care Stocks Mixed Late Afternoon
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
La FDA Aprueba Un Medicamento Con Un Nuevo Mecanismo De Acción Para El Tratamiento De La Esquizofrenia
US Equity Indexes Mixed as Treasury Yields Slip After Investors Weigh Easing in Inflation
Bristol-Myers Squibb Potential Scalp Psoriasis Treatment Meets Targets
Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
Express News | Bristol-Myers Squibb Co -Safety Profile in Psoriatyk Scalp Was Consistent With Established Safety Profile of Sotyktu
Express News | Bristol-Myers Squibb Co - Primary Endpoint Met With Significant Improvement in Ss-Pga Response
Express News | Bristol Myers Squibb Presents New Data From Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
FDA Approves New Bristol Myers Squibb Schizophrenia Drug
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
Bristol-Myers Squibb Analyst Ratings
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $57